Multi-regional clinical trials (MRCTs) introduce complications single-country studies never face: varying GMP and QP release requirements, customs regimes that don't talk to each other, multilingual labeling obligations, and site infrastructure that ranges from state-of-the-art to genuinely under-resourced. This guide walks through forecasting, packaging and labeling, distribution and cold chain, risk mitigation, and what to look for in a CRO/CDMO partner.
Key Takeaways
- Build IMP supply strategy into protocol design from day one, not after site selection
- Demand-led planning supported by IRT/RTSM cuts waste versus fixed supply-led models
- Multicountry labeling, customs, and comparator sourcing are the top delay sources
- Cold chain and depot design directly affect patient safety and data integrity
- Multi-region regulatory expertise reduces risk when trials expand into LMIC markets
What Is an IMP Supply Strategy and Why Multicountry Trials Are Different
An Investigational Medicinal Product (IMP) is any pharmaceutical form of an active ingredient, placebo, or reference product tested or used in a clinical trial. Under ICH E6(R3), finalized in 2025, sponsors carry direct GCP responsibility for how that product is manufactured, coded, labeled, packaged, stored, transported, and ultimately accounted for and destroyed.
An IMP supply strategy is the end-to-end plan for those obligations: demand forecasting, depot selection, country release sequencing, labeling and packaging, distribution to sites, and accountability through return or destruction.
That responsibility gets much harder across borders. A domestic trial has one GMP framework, one import authority, one language. A multicountry trial multiplies every one of those variables:
- Different GMP/QP release requirements per country
- Separate import authorizations (an IND in the US works nothing like a Clinical Trial Application in the EU)
- Multiple languages and country-specific regulatory label text
- Site infrastructure that varies widely, particularly in low- and middle-income countries (LMICs) Why this matters practically: none of these regulatory clocks are interchangeable. The FDA generally requires sponsors to wait 30 calendar days after IND submission before initiating a trial. The EU's Clinical Trials Regulation assesses Part II applications within 45 days of validation, with certain modifications reviewed on a 38-day clock. Treating these timelines as equivalent, or assuming one country's clock applies everywhere, is how start-up delays happen. That complexity needs regional regulatory context, not one desk interpreting every jurisdiction from afar. DRK Research Solutions operates across Europe, the Middle East, Asia, Africa, and the Americas, giving sponsors local insight in the countries where trials actually run.
Building a Robust Demand Forecasting and Supply Planning Strategy
Forecasting is the foundation that everything else sits on. Enrollment projections, dosing schedules, visit schedules, overage buffers, and manufacturing lead times all need to feed into one plan, not five disconnected spreadsheets.
Supply-Led vs. Demand-Led vs. Hybrid Models
Traditional supply-led planning stockpiles inventory upfront based on worst-case enrollment assumptions. It's simple, but it's wasteful. A 2017 review of 200 completed studies by Cenduit found that 62% of packaged and released material went unused, a clear sign of how far fixed forecasting can overshoot actual need.
Demand-led planning, driven by real-time IRT/RTSM data, ties resupply to actual enrollment and dosing rather than projections made months in advance. Most sponsors now land on a hybrid: enough buffer stock to prevent stockouts, paired with IRT-triggered resupply to avoid overproduction.
Get Supply Teams Into Protocol Design Early
Hybrid planning still fails when the protocol keeps moving. Protocol amendments are expensive: Tufts CSDD research found substantial amendments in 57% of protocols, and 45% were judged avoidable. Median direct costs hit $141,000 in Phase II and $535,000 in Phase III. Many of these changes touch dosing schedules, visit windows, or comparator arms, and each one ripples straight into supply plans.
Practical strategies to reduce waste and rework:
- Campaigned resupply — manufacture and ship in planned waves instead of one large upfront batch
- Pooling strategies — share inventory across sites or regions rather than siloing by country
- Country-specific enrollment modeling — faster-enrolling LMIC sites need different buffer logic than slower-recruiting established markets
- Early supply-team involvement — bring clinical supply teams in during protocol drafting, not after protocol lock
Packaging, Labeling, and Blinding Requirements Across Borders
GMP packaging rules already carry weight on their own. Layer on blinding requirements—over-encapsulation, matched kits, and double-dummy designs for active-controlled studies—and the packaging workstream becomes one of the most resource-intensive parts of MRCT supply.
Those pack and blind choices also drive label complexity: every kit configuration still has to satisfy each country’s language and regulatory text.
Why Labeling Multiplies Fast
Every participating country typically requires its own language and its own regulatory label text. A trial running in eight countries doesn't need one label — it may need eight distinct label variants per batch, each requiring its own translation, review, and approval cycle.
FDA rules require investigational drug packages to carry a specific caution statement. UK guidance requires IMPs not authorized in the UK to carry full labeling by default. The EU's Clinical Trials Regulation dossier separately addresses labeling as its own regulatory component. None of these requirements are interchangeable, and missing one delays the whole shipment.
Lock variables early. Finalize comparators, pack formats, and label text as early as possible in study start-up. Every later change cascades into rework across every country's label variant.
Flexibility strategies when the country mix isn't finalized:
- Use booklet labels with multiple language panels on a single label stock
- Design multilingual panels that can absorb late-added countries without a full reprint
- Apply just-in-time labeling closer to shipment, once country allocation is confirmed
Distribution, Depot Networks, Cold Chain, and Customs Across Countries
Depot placement is a balancing act. Sites need proximity for fast resupply, but depots also need to sit inside a jurisdiction with workable import rules and cold chain infrastructure.
Import and export authorization requirements vary sharply by country. A Clinical Trial Application in the EU and an IND in the US aren't equivalent processes, and neither should be treated as a stand-in for actual customs clearance time. These are separate regulatory clocks, and both need buffer time built around them.
Cold Chain Is Where Delays Turn Into Safety Issues
Temperature-sensitive IMPs are especially exposed at customs. Historical logistics data found an average temperature-excursion disposition time of 57 hours (range 6 to 114 hours). Customs clearance points were among the most frequent locations where those excursions occurred.
Comparator Sourcing and Manufacturing Concentration
Comparator sourcing creates a parallel supply problem. Active-controlled trials often require locally sourced comparator drugs in specific markets because of import restrictions on already-approved products. Sponsors then run two supply chains instead of one.
Manufacturing geography adds systemic exposure. FDA testimony found that as of 2019, only 28% of API manufacturing facilities supplying the US were domestic, with 72% located overseas. A single regional disruption—regulatory, political, or logistical—can ripple through IMP supply for trials worldwide.
Build distribution plans around these checkpoints:
- Place depots for import rules and cold-chain capacity, not site proximity alone
- Buffer regulatory authorization and customs clearance as separate clocks
- Source comparators locally where import limits block approved product movement
- Stress-test IMP supply against concentrated overseas API manufacturing regions
Risk Management and the Role of IRT/RTSM Technology
Supply disruptions in multicountry trials rarely stay local. A holdup in one region can stall enrollment elsewhere, so risk controls and IRT/RTSM need to work together from the start.
Common Supply Chain Risks in Multicountry Trials
| Risk | Mitigation |
|---|---|
| Enrollment acceleration outpacing supply | Trigger-based resupply tied to real-time enrollment data |
| Manufacturing/QP release delays | Build QP release lead time into the master schedule, not as an afterthought |
| Customs clearance holdups | Pre-clear documentation; maintain buffer stock at regional depots |
| Temperature excursions | Calibrated monitoring plus pre-agreed excursion disposition SOPs |
| Comparator unavailability | Qualify backup local sourcing early in countries with import restrictions |
How IRT/RTSM Reduces Multicountry Supply Risk
IRT automates randomization, drug assignment, and country-specific resupply triggers. That automation cuts the manual coordination errors that creep in when dozens of sites across multiple time zones manage supply by spreadsheet or phone call.
Real-time inventory visibility often matters more. When enrollment accelerates faster in one region than another, sponsors with connected IRT data can reallocate supply between countries instead of expediting new manufacturing runs at premium cost.
Choosing the Right CRO/CDMO Partner for Global IMP Supply
Coordinating forecasting, packaging, depots, cold chain, and customs through separate vendors in every country creates friction. Every handoff between vendors is a place where information gets lost, timelines slip, or accountability becomes unclear. A single coordinating partner offers real advantages:
- One escalation point instead of five vendor relationships per region
- Consistent data flow between forecasting, IRT, and depot management
- Faster decision-making when enrollment or supply conditions shift mid-trial Those advantages compound when one partner owns both local execution and global oversight. DRK Research Solutions brings over a decade of multi-regional clinical trial experience, with operations spanning Europe, the Middle East, Asia, Africa, and the Americas. That mix of local regulatory proficiency and global coordination matters most in underserved and LMIC markets, where infrastructure and import pathways can differ sharply from one neighboring country to the next. Local teams who understand a country's import rules and site conditions, backed by a coordinated global structure, are what keep site activation on schedule.
Frequently Asked Questions
What does IMP mean in clinical trials?
An Investigational Medicinal Product (IMP) is any pharmaceutical form of an active ingredient, placebo, or reference product tested in a clinical trial. Under ICH E6(R3), sponsors hold direct GCP responsibility for its manufacture, labeling, and accountability.
What are the 5 stages of clinical trials?
The five stages run from preclinical testing through Phase I (safety, 20–100 participants), Phase II (efficacy and side effects), Phase III (broader efficacy, 300–3,000 participants), and Phase IV (post-market surveillance). IMP supply needs scale up sharply from Phase I to Phase III.
How does multicountry trial supply differ from single-country supply?
Multicountry trials require separate customs authorizations, GMP/QP requirements, and label variants for each participating country. A single-country trial works under one regulatory framework; a multi-regional clinical trial (MRCT) manages several at once.
What is the difference between supply-led and demand-led IMP planning?
Supply-led planning stockpiles inventory based on upfront projections, often leading to waste. Demand-led planning ties resupply to real-time enrollment data via IRT. Most sponsors now use a hybrid of both.
How early should IMP supply planning start in a multicountry trial?
Supply planning should start during protocol design, not after site selection or protocol lock. Late involvement leads to costly amendments and packaging rework once comparators or dosing schedules change.
What happens to unused IMP at the end of a multicountry trial?
Sponsors must maintain records of delivery, use, return, and destruction under GCP, with reconciliation processes that vary by jurisdiction. Each country may have its own requirements for return, quarantine, or destruction certification.
